Cantor Fitzgerald Downgrades Tobira Therapeutics (TBRA) to Hold Following Takeover

September 21, 2016 9:12 AM EDT
Get Alerts TBRA Hot Sheet
Price: $40.70 --0%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 1 | Down: 2 | New: 2
Trade TBRA Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Cantor Fitzgerald downgraded Tobira Therapeutics (NASDAQ: TBRA) from Buy to Hold with a price target of $42.00 (from $19.00) after the company agreed to be acquired by Allergan.

For an analyst ratings summary and ratings history on Tobira Therapeutics click here. For more ratings news on Tobira Therapeutics click here.

Shares of Tobira Therapeutics closed at $38.91 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Cantor Fitzgerald

Add Your Comment